Birch Concepts

Birch BioMed is a clinical-stage regenerative medicine company focused on developing breakthrough therapies to prevent and reverse scarring and autoimmune diseases. The company's technology platform is based on research licensed from the University of British Columbia, targeting the molecular pathways responsible for fibrosis and immune dysfunction. Its lead product candidate, FS2, is a small molecule in Phase 2 development for the treatment of hypertrophic scars and keloids, demonstrating the potential to degrade existing scar tissue. Birch BioMed is also advancing AI-001, an immunotherapy designed to reverse Type 1 Diabetes by restoring immune tolerance. By addressing the root causes of fibrosis and autoimmunity, the company aims to provide transformative treatments for conditions with significant unmet medical needs.